Clindamycin

證據等級: L5

預測適應症: 10 個

Clindamycin: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Clindamycin is a lincosamide antibiotic with well-established use in treating bacterial infections including skin and soft tissue infections, anaerobic infections, pelvic inflammatory disease, and ocular toxoplasmosis. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis (rank 1, score 99.97%); however, the mechanistic rationale is biologically weak, and no supporting clinical trials or published literature were identified for this specific indication. Across all 10 predicted indications, the evidence remains at Level L4–L5, and a Hold decision is recommended pending further mechanistic and clinical validation.

Quick Overview

Item	Content
Original Indication	Not documented in South African regulatory data (no SAHPRA registrations on record)
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.97%
Evidence Level	L5
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby blocking peptide chain elongation. It has demonstrated efficacy against gram-positive cocci (including Staphylococcus aureus and Streptococcus spp.), anaerobes, and certain protozoa (notably Toxoplasma gondii, making it a recognised treatment for ocular toxoplasmosis).

Punctate epithelial keratoconjunctivitis (PEK) is primarily caused by adenoviral infection, dry eye disease, or drug toxicity — none of which is a bacterial process amenable to Clindamycin’s antibiotic mechanism. While ocular toxoplasmosis (a known Clindamycin indication) can produce secondary corneal involvement, the pathobiology of PEK is substantially distinct from toxoplasmal chorioretinitis.

The Evidence Pack’s mechanistic analysis notes that the high TxGNN score (0.9997) is most likely attributable to high node-density connections in the knowledge graph between Clindamycin and ocular network nodes, rather than a genuine therapeutic signal. No clinical trials and no published literature were retrieved to support this repurposing hypothesis. The biological plausibility of Clindamycin as a primary treatment for PEK is not currently supported.

Clinical Trial Evidence

Currently no related clinical trials registered for any of the 10 TxGNN-predicted indications.

Literature Evidence (Top Predicted Indication: Punctate Epithelial Keratoconjunctivitis)

Currently no related literature available for this specific indication.

Note: Limited indirect literature was retrieved for lower-ranked predicted indications. See the supplementary overview below for context.

Supplementary: Literature Retrieved for Secondary Predicted Indications

PMID	Year	Type	Journal	Indication Searched	Key Findings
22880135	2012	Retrospective Case Series	PLoS One	Exposure Keratitis	Prevalence and antibiotic susceptibility of MRSA vs MSSA ocular infections; clindamycin susceptibility patterns reported
24244625	2013	Retrospective Hospital Review	PLoS One	Exposure Keratitis	Clinical features and antibiotic susceptibility of S. aureus keratitis; MRSA vs MSSA comparison
11581057	2001	Case Report	Ophthalmology	Exposure Keratitis	First reported case of contact lens-related Bacillus cereus keratitis; indirect relevance only
33847093	2021	Retrospective Veterinary Study	Polish J Vet Sci	Exposure Keratitis	Feline ocular toxoplasmosis treatment outcomes; veterinary data, not directly applicable to humans
36684930	2022	Molecular Epidemiology (Veterinary)	Front Public Health	Non-Human Animal Disease	C. difficile genetic overlap between companion animals and humans; Clindamycin implicated as a CDI-inducing agent (negative signal)
40172204	2025	Epidemiological Study (Veterinary)	Appl Environ Microbiol	Non-Human Animal Disease	C. difficile in feral horse populations in Australia; veterinary epidemiology only
21908289	2011	In Vitro MIC Study (Veterinary)	J Vet Diagn Invest	Epidemic Keratoconjunctivitis	MIC data for Moraxella bovoculi in infectious bovine keratoconjunctivitis; bovine pathogen, not applicable to human adenoviral EKC
25261461	2014	Retrospective Field Epidemiology (Veterinary)	J Vet Diagn Invest	Epidemic Keratoconjunctivitis	Retrospective characterisation of Moraxella spp. in cattle IBK; veterinary data only

Important caveat: All retrieved literature is indirect, involves veterinary subjects or non-target pathogens, and does not constitute clinical evidence for the predicted human indications. Two papers (PMIDs 36684930, 40172204) contain a negative safety signal: Clindamycin is identified as a high-risk inducer of Clostridioides difficile infection (CDI), not a therapeutic agent in that context.

South Africa Market Information

Clindamycin is not currently registered with SAHPRA per this dataset. No product licences, dosage forms, or approved indications are on record.

Clinicians requiring Clindamycin for established indications (e.g., bacterial vaginosis, anaerobic infections, toxoplasmosis) should verify current SAHPRA registration status and Section 21 authorisation requirements via the SAHPRA online register.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information. In the absence of South African PI data in this Evidence Pack, healthcare professionals should note the following from established pharmacological knowledge:

CDI Risk: Clindamycin carries a well-documented risk of Clostridioides difficile-associated diarrhoea and pseudomembranous colitis. This is reflected in the retrieved literature (PMIDs 36684930, 40172204) and is a critical prescribing consideration.
Drug Interactions: No DDI data was returned by the query. Consult current interaction databases before co-prescribing.

Report adverse drug reactions to SAHPRA via the MedSafety reporting system.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 TxGNN-predicted indications for Clindamycin in this pack are rated L4–L5 evidence, with no supporting clinical trials registered and only indirect veterinary or non-specific literature retrieved. The top-ranked indication (punctate epithelial keratoconjunctivitis, score 99.97%) has no biological plausibility as a primary treatment target given Clindamycin’s antibiotic mechanism of action; the high score is attributable to knowledge graph topology, not therapeutic signal. Additionally, a negative CDI-induction signal was identified in the retrieved literature, warranting caution.

To proceed, the following is needed:

MOA data: Confirm full mechanism of action via DrugBank API (data gap DG002) to enable proper mechanistic-link analysis
SAHPRA status clarification: Verify current SAHPRA registration status; if the drug is commercially available in South Africa under a different dataset snapshot, obtain PI document for safety and contraindication data (data gap DG001)
Biological plausibility review: Commission a structured mechanistic review for any ocular indication under consideration, specifically examining whether Clindamycin’s known anti-Toxoplasma activity provides a credible secondary-infection rationale
Hypothesis refinement: Consider re-running TxGNN with edge-weight normalisation to reduce false-positive signals from high-density KG nodes in the Clindamycin–ophthalmic network
Clinical feasibility assessment: If the ocular toxoplasmosis link is to be explored further, redirect query to chorioretinitis or uveitis (known indications) rather than keratoconjunctivitis subtypes

Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All predictions should be interpreted in the context of established clinical guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.